A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb).

Trial Profile

A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb).

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Fimasartan (Primary) ; Candesartan cilexetil
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Boryung Pharmaceutical
  • Most Recent Events

    • 06 May 2016 Primary endpoint (Sitting Diastolic Blood Pressure) has not been met, according to results published in the Clinical Therapeutics.
    • 06 May 2016 Results assessing antihypertensive efficacy of fimasartan published in the Clinical Therapeutics.
    • 23 Aug 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top